News + Font Resize -

Oramed receives Israel patent for oral administration of GLP-1
Jerusalem | Monday, January 19, 2015, 15:00 Hrs  [IST]

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that the Israel Patent Office has granted the company's patent for its invention, titled "Methods and Compositions for Oral Administrations of Exenatide."

Glucagon-like peptide-1 (GLP-1) is an incretin hormone that stimulates the secretion of insulin from the pancreas. Exenatide, a GLP-1 analog, is currently marketed in injectable form only, and is indicated for treatment of type 2 diabetes. Exenatide induces insulin release at increased glucose levels and causes a feeling of satiety, which results in reduced food intake and weight loss. Oramed's oral GLP-1 capsule based on the company's POD technology could significantly increase compliance and become a valuable tool in the treatment of diabetes.

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (POD) technology is based on over 30 years of research by top scientists at Jerusalem's Hadassah Medical Center.

Post Your Comment

 

Enquiry Form